AR038041A1 - Metodo para el tratamiento de trastornos oseos - Google Patents

Metodo para el tratamiento de trastornos oseos

Info

Publication number
AR038041A1
AR038041A1 ARP020104997A ARP020104997A AR038041A1 AR 038041 A1 AR038041 A1 AR 038041A1 AR P020104997 A ARP020104997 A AR P020104997A AR P020104997 A ARP020104997 A AR P020104997A AR 038041 A1 AR038041 A1 AR 038041A1
Authority
AR
Argentina
Prior art keywords
during
bisphosphonate
period
disorders
oseos
Prior art date
Application number
ARP020104997A
Other languages
English (en)
Inventor
Arkadi Aaron Chines
Pamela Jean Schofield
David Ernest Burgio
Den Berg Henry Van
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23352430&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR038041(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of AR038041A1 publication Critical patent/AR038041A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Kit o conjunto para aumentar la masa ósea según un régimen que comprende dosis unitarias de bisfosfonato, como ser risedronato, ácido alendrónico, pamidronato, tiludronato, clodronato, cimadronato, ibandronato, zolendronato, sus sales y ésteres, durante un periodo de carga de 7 a 180 días, seguido de dosis unitarias menores de bisfosfonato durante un período de mantenimiento, con un medio para facilitar su cumplimiento. El uso de un bisfosfonato para fabricar un kit útil para un método que comprende su administración durante un período de carga y en menor dosis, durante un período de mantenimiento. Se aplica para aumentar la masa ósea, reducción de fracturas en osteoporosis y tratar trastornos metabólicos óseos, con mayor rapidez.
ARP020104997A 2001-12-21 2002-12-19 Metodo para el tratamiento de trastornos oseos AR038041A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34487501P 2001-12-21 2001-12-21

Publications (1)

Publication Number Publication Date
AR038041A1 true AR038041A1 (es) 2004-12-22

Family

ID=23352430

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020104997A AR038041A1 (es) 2001-12-21 2002-12-19 Metodo para el tratamiento de trastornos oseos

Country Status (24)

Country Link
US (5) US20030118634A1 (es)
EP (1) EP1455796A1 (es)
JP (1) JP2005514400A (es)
KR (1) KR100638122B1 (es)
CN (1) CN100479823C (es)
AR (1) AR038041A1 (es)
AU (1) AU2002360619B2 (es)
CA (1) CA2469779C (es)
CZ (1) CZ2004690A3 (es)
HK (1) HK1087039A1 (es)
HU (1) HUP0402267A3 (es)
IL (2) IL162053A0 (es)
MA (1) MA27157A1 (es)
MX (1) MXPA04006027A (es)
MY (1) MY147886A (es)
NO (1) NO340249B1 (es)
NZ (1) NZ532994A (es)
PE (1) PE20030743A1 (es)
PL (1) PL371264A1 (es)
RU (1) RU2294203C2 (es)
SK (1) SK2532004A3 (es)
TW (1) TWI349553B (es)
WO (1) WO2003055496A1 (es)
ZA (1) ZA200404007B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005514400A (ja) * 2001-12-21 2005-05-19 ザ プロクター アンド ギャンブル カンパニー 骨疾患の治療方法
ATE376444T1 (de) * 2002-05-10 2007-11-15 Hoffmann La Roche Ibandronsäure zur behandlung und vorbeugung von osteoporose
US20040097468A1 (en) * 2002-11-20 2004-05-20 Wimalawansa Sunil J. Method of treating osteoporosis and other bone disorders with upfront loading of bisphosphonates, and kits for such treatment
BR0309691A (pt) * 2002-12-20 2005-08-02 Hoffmann La Roche Formulação de ibandronato em alta dose
CA2566798A1 (en) * 2004-05-24 2005-12-08 The Procter & Gamble Company Enteric solid oral dosage form of bisphosphonate containing a chelating agent
WO2006020009A1 (en) * 2004-07-23 2006-02-23 The Procter & Gamble Company Solid oral dosage form of a bisphosphonate containing a chelating agent
US20070191315A1 (en) * 2006-02-16 2007-08-16 Bengt Bergstrom Method for administering ibandronate

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA777769A (en) * 1963-03-18 1968-02-06 H. Roy Clarence Substituted methylene diphosphonic acid compounds and detergent compositions
DE2405254C2 (de) * 1974-02-04 1982-05-27 Henkel KGaA, 4000 Düsseldorf Verwendung von 3-Amino-1-Hydroxypropan-1, 1-diphosphonsäure oder ihrer wasserlöslichen Salze bei der Beeinflußung von Calciumstoffwechselstörungen im menschlichen oder tierischen Körper
DE2534391C2 (de) * 1975-08-01 1983-01-13 Henkel KGaA, 4000 Düsseldorf 1-Hydroxy-3-aminoalkan-1,1-diphosphonsäuren
DE2745083C2 (de) * 1977-10-07 1985-05-02 Henkel KGaA, 4000 Düsseldorf Hydroxydiphosphonsäuren und Verfahren zu deren Herstellung
US4252742A (en) * 1979-07-13 1981-02-24 Ciba-Geigy Corporation Chemical process for the preparation of 2,6-dialkylcyclohexylamines from 2,6-dialkylphenols
DE2943498C2 (de) * 1979-10-27 1983-01-27 Henkel KGaA, 4000 Düsseldorf Verfahren zur Herstellung von 3-Amino-1-hydroxypropan-1,1-diphosphonsäure
DE3016289A1 (de) * 1980-04-28 1981-10-29 Henkel KGaA, 4000 Düsseldorf Verfahren zur herstellung von omega -amino-1-hydroxyalkyliden-1,1-bis-phosphonsaeuren
IT1201087B (it) * 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
FR2531088B1 (fr) * 1982-07-29 1987-08-28 Sanofi Sa Produits anti-inflammatoires derives de l'acide methylenediphosphonique et leur procede de preparation
DE3434667A1 (de) * 1984-09-21 1986-04-03 Henkel KGaA, 4000 Düsseldorf 4-dimethylamino-1-hydroxybutan-1,1-diphosphonsaeure, deren wasserloesliche salze, verfahren zu ihrer herstellung sowie ihre verwendung
IT1196315B (it) * 1984-10-29 1988-11-16 Gentili Ist Spa Procedimento per la preparazione di acidi difosfonici
IL77243A (en) * 1984-12-21 1996-11-14 Procter & Gamble Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds
US4812311A (en) * 1984-12-21 1989-03-14 The Procter & Gamble Company Kit for use in the treatment of osteoporosis
DE3512536A1 (de) * 1985-04-06 1986-10-16 Boehringer Mannheim Gmbh, 6800 Mannheim Neue diphosphonsaeure-derivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US4761406A (en) * 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
DE3540150A1 (de) * 1985-11-13 1987-05-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3623397A1 (de) * 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3626058A1 (de) * 1986-08-01 1988-02-11 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3640938A1 (de) * 1986-11-29 1988-06-01 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindung enthaltende arzneimittel
CA1339805C (en) * 1988-01-20 1998-04-07 Yasuo Isomura (cycloalkylamino)methylenebis(phosphonic acid) and medicines containing the same as an active
EP0333082A3 (en) * 1988-03-15 1991-05-02 Takeda Chemical Industries, Ltd. Cephem compounds, their production and use
GB2217988B (en) * 1988-04-11 1992-04-01 Gould Leonard W Regimen for increasing bone density in humans
DE3822650A1 (de) * 1988-07-05 1990-02-01 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US5018651A (en) * 1988-12-27 1991-05-28 Hull Harold L Side or end dump article carrier
DE3917153A1 (de) * 1989-05-26 1990-11-29 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US4922007A (en) * 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
NL8902727A (nl) * 1989-11-06 1991-06-03 Philips Nv Objecthouder voor ondersteuning van een object in een geladen deeltjesbundelsysteem.
US5356887A (en) * 1990-01-31 1994-10-18 Merck & Co., Inc. Pharmaceutical compositions containing insoluble calcium salts of amino-hydroxybutylidene bisphoshonic acids
US5019651A (en) * 1990-06-20 1991-05-28 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
TW237386B (es) * 1992-04-15 1995-01-01 Ciba Geigy
ES2118967T3 (es) * 1992-05-29 1998-10-01 Procter & Gamble Pharma Compuestos de fosfonato que contienen nitrogeno cuaternario para tratar un metabolismo anormal del calcio y fosfato asi como el calculo y la placa dentales.
US5391743A (en) * 1992-05-29 1995-02-21 Procter & Gamble Pharmaceuticals, Inc. Quaternary nitrogen-containing phosphonate compounds, pharmaceutical compositions, and methods of treating abnormal calcium and phosphate metabolism and methods of treating and preventing dental calculus and plaque
DE69324684T2 (de) * 1992-06-30 1999-11-25 Procter & Gamble Pharma Arzneimitteln zur behandlung von arthritis die phosphonate und nsaids enthalten
US5358941A (en) * 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
FR2703590B1 (fr) * 1993-04-05 1995-06-30 Sanofi Elf Utilisation de derives d'acide bisphosphonique pour la preparation de medicaments destines a favoriser la reparation osseuse .
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
US20010007863A1 (en) * 1998-06-18 2001-07-12 Merck & Co., Inc. Wet granulation formulation for bisphosphonic acids
US5462932A (en) * 1994-05-17 1995-10-31 Merck & Co., Inc. Oral liquid alendronate formulations
US6008206A (en) * 1994-09-21 1999-12-28 Merck & Co., Inc. Sodium alendronate preparation for local administration
US20010051616A1 (en) * 1995-02-17 2001-12-13 David B. Karpf Method of lessening the risk of vertebral fractures
CA2223101A1 (en) * 1995-06-07 1996-12-19 Co.Don Gmbh Gesellschaft Fur Molekulare Medizin Und Biotechnologie Standardized, primary osteoblast cell cultures from osteoporotic patients and their use in the diagnosis of osteoporosis and in testing potential osteoporosis therapeutic agents
DE19615812A1 (de) * 1996-04-20 1997-10-23 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation
GB2324726A (en) * 1997-05-01 1998-11-04 Merck & Co Inc Combination Therapy for the Treatment of Osteoporosis
US5994329A (en) * 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
US6432932B1 (en) * 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
US6124314A (en) * 1997-10-10 2000-09-26 Pfizer Inc. Osteoporosis compounds
JP2002519305A (ja) * 1998-06-24 2002-07-02 メルク エンド カムパニー インコーポレーテッド 骨吸収阻害用の組成物および方法
IT1303672B1 (it) * 1998-07-28 2001-02-23 Nicox Sa Sali nitrati di farmaci attivi nei disordini ossei
EP0998933A1 (de) * 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Verfahren zur Herstellung von bisphosphonathaltigen pharmazeutischen Zusammensetzungen zur oralen Applikation
EP0998932A1 (de) * 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung
BR9915927A (pt) * 1998-12-04 2001-08-21 Roche Diagnostics Gmbh Uso de ácido ibandrÈnico ou seus sais ou ésteres fisiologicamente compatìveis
US6468559B1 (en) * 2000-04-28 2002-10-22 Lipocine, Inc. Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
MXPA03000520A (es) * 2000-07-17 2003-10-06 Yamanouchi Pharma Co Ltd Composicion farmaceutica mejorada en absorbabilidad peroral..
AU2001272916A1 (en) * 2000-07-19 2002-02-05 Eli Lilly And Company Method for enhancing bone mineral density gain by administration of raloxifene
US6638920B2 (en) * 2000-07-21 2003-10-28 Merck & Co., Inc. Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses
ES2243457T3 (es) * 2001-01-23 2005-12-01 Gador S.A. Composicion que comprende bifosfonatos para la prevencion y/o tratamiento de trastornos metabolicos de huesos, procedimiento de preparacion de dicha composicion y usos de la misma.
AR034199A1 (es) * 2001-02-01 2004-02-04 Riderway Corp Composicion farmacologica liquida para el tratamiento de enfermedades oseas y procedimientos para su elaboracion
SK9862003A3 (en) * 2001-02-06 2004-02-03 Royal Alexandra Hosp Children A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis
CN1492763B (zh) * 2001-03-01 2012-05-23 艾米斯菲尔技术有限公司 用于递送二膦酸盐的组合物
CA2445922A1 (en) * 2001-05-10 2002-11-21 Merck & Co., Inc. Estrogen receptor modulators
WO2003051373A1 (en) * 2001-12-13 2003-06-26 Merck & Co., Inc. Liquid bisphosphonate formulations for bone disorders
US20050070504A1 (en) * 2001-12-21 2005-03-31 The Procter & Gamble Co. Risedronate compositions and their methods of use
JP2005514400A (ja) * 2001-12-21 2005-05-19 ザ プロクター アンド ギャンブル カンパニー 骨疾患の治療方法
US7488496B2 (en) * 2002-03-06 2009-02-10 Christer Rosen Effervescent compositions comprising bisphosphonates and methods related thereto
CA2480814A1 (en) * 2002-04-05 2003-10-23 Merck & Co., Inc. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
ATE376444T1 (de) * 2002-05-10 2007-11-15 Hoffmann La Roche Ibandronsäure zur behandlung und vorbeugung von osteoporose
US20040188316A1 (en) * 2003-03-26 2004-09-30 The Procter & Gamble Company Kit for pharmaceutical use

Also Published As

Publication number Publication date
US20080214505A1 (en) 2008-09-04
MY147886A (en) 2013-01-31
US20080261924A1 (en) 2008-10-23
NO340249B1 (no) 2017-03-27
TWI349553B (en) 2011-10-01
SK2532004A3 (en) 2004-11-03
TW200301704A (en) 2003-07-16
NO20043113L (no) 2004-09-01
AU2002360619B2 (en) 2006-10-05
US20080260827A1 (en) 2008-10-23
US20030118634A1 (en) 2003-06-26
HUP0402267A2 (hu) 2005-02-28
NZ532994A (en) 2008-05-30
CN1723024A (zh) 2006-01-18
AU2002360619A1 (en) 2003-07-15
HUP0402267A3 (en) 2007-05-29
IL162053A (en) 2009-09-22
KR20040065283A (ko) 2004-07-21
PE20030743A1 (es) 2003-10-22
JP2005514400A (ja) 2005-05-19
CN100479823C (zh) 2009-04-22
IL162053A0 (en) 2005-11-20
ZA200404007B (en) 2005-07-27
CA2469779A1 (en) 2003-07-10
CA2469779C (en) 2008-02-12
US20070166237A1 (en) 2007-07-19
KR100638122B1 (ko) 2006-10-24
WO2003055496A1 (en) 2003-07-10
PL371264A1 (en) 2005-06-13
MXPA04006027A (es) 2004-09-27
EP1455796A1 (en) 2004-09-15
HK1087039A1 (en) 2006-10-06
CZ2004690A3 (cs) 2004-09-15
RU2004122433A (ru) 2005-03-10
RU2294203C2 (ru) 2007-02-27
MA27157A1 (fr) 2005-01-03

Similar Documents

Publication Publication Date Title
NZ545804A (en) Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-or-vitamin D derivatives and a bisphosphonate
IL155363A0 (en) Use of bisphosphonates for pain treatment
AR049022A1 (es) Formas de dosificacion de bifosfonatos
RU2009134119A (ru) Инъецируемый кальций-фосфатный цемент, высвобождающий ингибитор резорбции костной ткани
DE60113537D1 (de) Methode zur verabreichung von biphosphonaten
AR045935A1 (es) Barras solidas y pastas de fosfato de calcio inyectables para el suministro de proteinas osteogenicas
HRP20041013B1 (hr) Formulacija visoke doze ibandronata
AR038041A1 (es) Metodo para el tratamiento de trastornos oseos
AR039548A1 (es) Vehiculos solidos inyectables de acido hialuronico para la administracion de proteinas osteogenicas
YU27395A (sh) Mokra granulacija formulacije za bisfosfinske kiseline
EE05603B1 (et) Alendronaadi kasutamine ravimi valmistamiseks osteoporoosi raviks
ATE330616T1 (de) Verabreichung von bisphosphonaten durch inhalation zur behandlung von knochenresorption und osteoporosis
AR020017A1 (es) Integracion osea
Lazar et al. Bisphosphonates in bone diseases treatment
Gavrić et al. Osteonecrosis of the jaw as a serious adverse effect of bisphosphonate therapy and its indistinct etiopathogenesis
Loli Bisphosphonates and orthodontic tooth movement: a systematic review
YU1800A (sh) Upotreba bisfosfonata za proizvodnju leka za inhibiranje resorpcije kostiju

Legal Events

Date Code Title Description
FC Refusal